MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
34.960
-0.800 (-2.24%)
As of 10:23AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close35.760
Open35.870
Bid35.270 x 1100
Ask35.260 x 800
Day's Range34.940 - 36.090
52 Week Range30.330 - 47.820
Volume1,677,030
Avg. Volume4,785,396
Market Cap18.026B
Beta (3Y Monthly)1.30
PE Ratio (TTM)40.32
EPS (TTM)0.867
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2007-06-27
1y Target Est44.63
Trade prices are not sourced from all markets
  • Stocks on the move: mylan n.v, mosaic company and more
    Yahoo Finance Video8 days ago

    Stocks on the move: mylan n.v, mosaic company and more

    Stocks on the move in midday trading. Mylan N.V. up by 15%, Mosaic Company up by 6% and more. Yahoo Finance's Julie Hyman discuss.

  • Thomson Reuters StreetEvents17 hours ago

    Edited Transcript of MYL earnings conference call or presentation 5-Nov-18 10:00pm GMT

    Q3 2018 Mylan NV Earnings Call

  • See what the IHS Markit Score report has to say about Mylan NV.
    Markit4 days ago

    See what the IHS Markit Score report has to say about Mylan NV.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Reuters5 days ago

    Mylan and Theravance's COPD treatment gets FDA approval

    Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems. The treatment, Yupelri https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf, is a once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough. Yupelri belongs to a class of drugs called long-acting muscarinic antagonists (LAMA), with the existing treatment options primarily being hand-held devices such as Boehringer Ingelheim's Spiriva.

  • Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3
    Zacks5 days ago

    Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3

    Momenta (MNTA) posts narrower-than-expected loss in the third quarter, while revenues fall short of estimates.

  • PR Newswire5 days ago

    Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease

    DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the  New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year.

  • Hedge Funds Think This Drugmaker is on the Verge of a Breakout
    Insider Monkey6 days ago

    Hedge Funds Think This Drugmaker is on the Verge of a Breakout

    Concerns over rising interest rates and expected further rate increases have hit several stocks hard since the end of the third quarter. The NASDAQ and Russell 2000 indices are already in correction territory. More importantly, the Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by about 4 percentage points in October. Hedge […]

  • Mylan’s Major Drivers: Biosimilars and Asset Acquisitions
    Market Realist6 days ago

    Mylan’s Major Drivers: Biosimilars and Asset Acquisitions

    On June 4, the FDA issued a press release announcing regulatory approval for a biosimilar version of Amgen’s (AMGN) Neulasta and Mylan’s (MYL) Fulphilia. On September 20, the European Medicines Agency issued a press release announcing a positive opinion from the Committee for Medicinal Products for Human Use for Fulphila. According to Mylan’s investor presentation, Fulphila is targeting a global market opportunity worth more than $5.0 billion.

  • Europe: Key Growth Driver for Mylan
    Market Realist6 days ago

    Europe: Key Growth Driver for Mylan

    In the third quarter, Mylan (MYL) reported net sales of $1.04 billion from the European market, which is a flat performance on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the company has witnessed strong demand for branded generics and over-the-counter products in the European market. According to Mylan’s investor presentation, the company has a presence in 35 countries and offers more than 1,500 products in the European market. Mylan is already a leader in terms of value and volume in France and Italy’s generic drug markets.

  • InvestorPlace6 days ago

    Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow

    Whenever a stock shoots higher, value investors justifiably hesitate on trading it. The stock priced in the good news already, leaving few extra gains ahead. So when Mylan N.V. (NASDAQ: MYL) rose by over 15% on the week, the best thing investors may do before buying Mylan stock is to look at the quarterly earnings result in detail.

  • Mylan: Why North America Is a Major Market
    Market Realist6 days ago

    Mylan: Why North America Is a Major Market

    In the third quarter, Mylan (MYL) reported net sales of $1.01 billion from the North American market, which is a 14% decline on a YoY (year-over-year) basis. According to Mylan’s third-quarter earnings conference call, the revenue drop was due to reduced sales volumes of existing products, including Epipen. According to Mylan’s third-quarter earnings conference call, the lower sales volumes in the third quarter were due to the timing of customers’ purchases and the restructuring and remediation program that was started at the Morgantown manufacturing facility in the second quarter.

  • Mylan’s Earnings Projections in 2018
    Market Realist7 days ago

    Mylan’s Earnings Projections in 2018

    According to Mylan’s (MYL) third-quarter earnings conference call, the company expects to witness an adjusted EPS of $4.55–$4.90 in 2018. Wall Street analysts expect Mylan to report an adjusted EPS of $4.70 in 2018, which will be a rise of 2.99% YoY. Wall Street analysts also expect Mylan to report an adjusted EPS of $5.59 in 2020, which will be a rise of 8.47% YoY.

  • Analyzing Mylan’s Revenue Projections in 2018
    Market Realist7 days ago

    Analyzing Mylan’s Revenue Projections in 2018

    According to Mylan’s (MYL) third-quarter earnings conference call, the company expects to witness revenues of $11.25 billion–$12.25 billion in 2018. Wall Street analysts expect Mylan to report revenues of $11.50 billion in 2018, which will be a decline of 3.44% YoY. Wall Street analysts also expect Mylan to report revenues of $12.46 billion in 2020, which will be a rise of 3.72% YoY.

  • Motley Fool7 days ago

    Momenta Pharmaceuticals Inc (MNTA) Q3 2018 Earnings Conference Call Transcript

    MNTA earnings call for the period ending September 30, 2018.

  • Mylan: Analysts’ Recommendations in November
    Market Realist7 days ago

    Mylan: Analysts’ Recommendations in November

    On November 6, Mylan (MYL) closed at $36.43, which was 16.13% higher than its previous closing price. The stock was trading 12.33% higher than its closing price of $32.43 on November 1. Based on Mylan’s closing price on November 6, the company witnessed returns of 16.35% in the last week, 3.17% in the last month, and -7.14% in the last quarter.

  • Company News For Nov 7, 2018
    Zacks7 days ago

    Company News For Nov 7, 2018

    Companies In The News Are: ELF,ABC,MNK,MYL

  • Wall Street thought Mylan was headed for disaster—now, analysts are raving
    MarketWatch7 days ago

    Wall Street thought Mylan was headed for disaster—now, analysts are raving

    Generic drugmaker Mylan’s last quarterly report was marked by poor financial results and other discouraging developments, leading many investors to worry that the sky was falling, according to Leerink analyst Ami Fadia. Mylan’s (MYL)third-quarter results, which included a profit beat, sent the company’s shares up 16% on Tuesday and spurred a turnaround in Wall Street sentiment. “Bigger picture, we see recent weakness in MYL as overdone,” said J.P. Morgan analyst Chris Schott.

  • 3 Big Stock Charts for Wednesday: Walt Disney, Skyworks Solutions and PG&E Corporation
    InvestorPlace7 days ago

    3 Big Stock Charts for Wednesday: Walt Disney, Skyworks Solutions and PG&E Corporation

    Election day was unsurprisingly tame, with most investors willing to wait at least one more day to make trades so they can make some decisions in light of who is (or isn’t) in office. Click to Enlarge • The weekly chart isn’t tough to interpret.

  • Barrons.com7 days ago

    The Market Is Finally Embracing Long-Unloved Drug Stocks

    Bausch Health, Mallinckrodt, and Mylan have rallied after years in the doghouse. Mylan could be the next to rebound.

  • Reuters7 days ago

    US STOCKS-S&P 500 futures up as Democrats capture U.S. House

    U.S. stock futures held onto gains on Tuesday after media projections showed the Democrats winning control of the House of Representatives in U.S. midterm congressional elections. With President Donald Trump's Republican party holding onto their majority in the Senate, according to CNN, NBC and ABC News, the results were in line with expectations on Wall Street that Washington was set for gridlock.

  • Barrons.com8 days ago

    Dow Gains 173 Points Because the Market Only Cares That Midterms Are Almost Over

    Though many believe gridlock in Washington is good for Wall Street, stocks usually rally after the midterms no matter what the results are.

  • Reuters8 days ago

    US STOCKS-Wall St gains as investors look to U.S. elections

    Wall Street's major indexes closed higher on Tuesday as voters headed to the polls in U.S. midterm congressional elections and investors hoped the result would provide some relief for stocks after prolonged uncertainty. Some stocks such as CVS Health Corp and Mylan NV were boosted by strong earnings, but despite a late afternoon spike in buying, trading volume was relatively thin as many investors held back on making big bets in case of a surprise election outcome. Wall Street had been expecting that President Donald Trump's Republican party would lose control of the House of Representatives, while retaining the Senate.

  • Why Mylan, Mosaic, and Martin Marietta Materials Jumped Today
    Motley Fool8 days ago

    Why Mylan, Mosaic, and Martin Marietta Materials Jumped Today

    Find out how these stocks fared on Election Day.

  • 5 Top Stock Trades for Wednesday: AMD’s Teaming Up With Amazon?
    InvestorPlace8 days ago

    5 Top Stock Trades for Wednesday: AMD’s Teaming Up With Amazon?

    Can they hold above this mark and get back above channel support (blue line)? If it can, the 21-day near $23 and channel resistance near $24 are in the cards. A top and bottom-line beat propelled shares of CVS Health (NYSE:CVS) higher by 5% on Tuesday.

  • MarketPulse: Mylan Surges to Keep Health Care Stocks Well Above Flatline
    Investing.com8 days ago

    MarketPulse: Mylan Surges to Keep Health Care Stocks Well Above Flatline

    Investing.com - A pulsating rally in shares of Mylan and CVS Health Tuesday offset weakness in Eli Lilly, keeping the broader health care sector well above the flatline.